*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.
Scholar Rock Holding's upcoming earnings report on November 14, 2025, is poised to capture attention, particularly following the company's impressive 335% surge in stock price due to positive phase 3 data for its spinal muscular atrophy treatment, apitegromab. This development underscores the company's strategic focus on advancing its clinical pipeline, which has been a key driver of investor optimism despite previous financial challenges. With a market cap nearing $2.7 billion, Scholar Rock is expected to report an EPS of $0.00, aligning with the whisper number, and a modest revenue estimate of $56,000. Recent strategic moves, such as increased shareholdings by Raymond James Financial and Millennium Management, reflect growing confidence in the company's potential. As Scholar Rock navigates the complexities of the biotech sector, the acceptance of its Biologics License Application (BLA) for apitegromab by the FDA offers a promising outlook, potentially offsetting past earnings misses and setting the stage for future growth.
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.
Website: https://www.scholarrock.com
Average Sentiment Score:
Overall Sentiment: